Clinical efficacy of 'Tomudex' (raltitrexed) in advanced colorectal cancer

Anti-Cancer Drugs

Volumn 8, Issue SUPPL. 2, 1997, Pages

  Kerr, David J ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

5 fluorouracil; Advanced colorectal cancer; Efficacy; Raltitrexed; Safety; Tolerability; Tomudex

Indexed keywords

FLUOROURACIL; RALTITREXED;

CANCER REGRESSION; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; CONFERENCE PAPER; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; CLINICAL TRIALS, PHASE III; COLORECTAL NEOPLASMS; QUINAZOLINES; THIOPHENES;

EID: 0030847327     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199708002-00003     Document Type: Conference Paper

References (22)

1. Machover D, Goldschmidt E, Chollet P, et al.: Treatment of advanced colorectal and gastric adenocarcinoma with 5-fluorouracil and high dose folinic acid. J Clin Oncol 1986, 4:685-696.
2. Doroshow JH, Multhauf F, Leang L, et al.: Prospective randomized comparison of fluorouracil versus fluorouracil and high-dose continuous infusion leucovorin calcium for the treatment of advanced measurable colorectal cancer in patients previously unexposed to chemotherapy. J Clin Oncol 1990, 8:491-501.
3. Labianca R, Pancera G, Aitini E, et al.: Folinic acid + 5-fluorouracil (5-FU) versus equidose 5-FU in advanced colorectal cancer. Phase III study of 'GISCAD' (Italian Group for the Study of Digestive Tract Cancer). Ann Oncol 1991, 2:673-679.
4. Moertel CG: Chemotherapy for colorectal cancer. N Engl J Med 1994, 330:1136-1141.
5. Caudry M, Bonnel C, Floquet A, et al.: A randomized study of bolus fluorouracil plus folinic acid versus 21-day fluorouracil infusion alone or in association with cyclophosphamide and mitomycin C in advanced colorectal carcinoma. Am J Clin Oncol 1995, 18:118-125.
6. Jackman AL, Farrugia DC, Gibson W, et al.: ZD1694 ('Tomudex'): a new thymidylate synthase inhibitor with activity in colorectal cancer. Eur J Cancer 1995, 31A:1277-1282.
7. Cunningham D, Zalcberg J, Smith IE, et al.: 'Tomudex', a novel, specific thymidylate synthase inhibitor with clinical anti-tumour activity in a range of solid tumours [abstract 0904]. Ann Oncol 1994, 5 (suppl 8):179.
8. Zalcberg JR, Cunningham D, Van Cutsem E, et al.: ZD1694: a novel thymidylate synthase inhibitor with substantial activity in the treatment of patients with advanced colorectal cancer. J Clin Oncol 1996, 14:716-721.
9. Poon MA, O'Connell MJ, Wieand HS, et al.: Biochemical modulation of fluorouracil: evidence of significant improvement in survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 1989, 7:1407-1418.
10. Judson IR: 'Tomudex' (raltitrexed) development: preclinical, phase I and II studies. Anticancer Drugs 1997, 8 (suppl 2):S5-S9.
11. Valone FH, Friedman MA, Wittlinger PS, et al.: Treatment of patients with advanced colorectal carcinomas with fluorouracil alone, high dose leucovorin plus fluorouracil or sequential methotrexate, fluorouracil and leucovorin: a randomized trial of the Northern California Oncology Group. J Clin Oncol 1989, 7:1427-1436.
12. Kochwa W: 5-fluorouracil (5-FU) plus interferon 2 alpha (Roferon-A) versus 5-FU plus leucovorin (LV) in metastatic colorectal cancer: results of a multicentre multinational phase III study [abstract]. Am Soc Clin Oncol 1993, 12:562.
13. Scheithauer W, Depisch D, Kornek G, et al.: Randomized comparison of fluorouracil and leucovorin therapy versus fluorouracil, leucovorin and cisplatin therapy in patients with advanced colorectal cancer. Cancer 1994, 73:1562-1568.
14. Valsecchi R, Labianca R, Cascinu S, et al.: High dose (HD) versus low dose (LD) L-leucovorin (LLV) as a modulator of 5-days 5-fluorouracil in advanced CRC: a GISCAD phase III study. Proc Am Soc Clin Oncol 1995, 14:457.
15. Scheithauer W, Rosen H, Kornek GV, Sebesta C, Depisch D: Randomized comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. BMJ 1993, 306:752-755.
16. Smyth JF, Hardcastle JD, Denton G, et al.: Two phase III trials of tauromustine (TCNU) in advanced colorectal cancer. Ann Oncol 1995, 6:948-949.
17. Poon MA, O'Connell MJ, Wieand HS, et al.: Biochemical modulation of fluorouracil with leucovorin: confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer. J Clin Oncol 1991, 9:1967-1972.
18. Bobbio-Pallavicini E, Porta C, Moroni M, et al.: Folinic acid does improve 5-fluorouracil activity in vivo: results of a phase III study comparing 5-fluorouracil to 5-fluorouracil and folinic acid in advanced colon cancer patients. J Chemother 1993, 5:52-55.
19. Buroker TR, O'Connell MJ, Wieand HS, et al.: Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer. J Clin Oncol 1994, 12:14-20.
20. Corfu Study Group: Phase III randomized study of two fluorouracil combinations with either interferon alfa-2a or leucovorin for advanced colorectal cancer. J Clin Oncol 1995, 13:921-928.
21. Recchia F, Nuzzo A, Lalli A, et al.: Randomized trial of 5-fluorouracil and high-dose folinic acid with or without alpha-2B interferon in advanced colorectal cancer. Am J Clin Oncol 1996, 19:301-304.
22. Zalcberg J: Overview of the tolerability of 'Tomudex' (raltitrexed): collective clinical experience in advanced colorectal cancer. Anticancer Drugs 1997, 8 (suppl 2):S17-S22.